Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: Predictors and moderators of treatment response

Joan Rosenbaum Asaknow, Graham Emslie, Greg Clarke, Karen Wagner, Anthony Spirito, Benedetto Vitiello, Satish Iyengar, Wael Shamseddeen, Louise Ritz, Boris Birmaher, Neal Ryan, Betsy Kennard, Taryn Mayes, Lynn DeBar, James McCracken, Michael Strober, Robert Suddath, Henrietta Leonard, Giovanna Porta, Martin KellerDavid Brent

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

Objective: To advance knowledge regarding strategies for treating selective serotonin reuptake inhibitor (SSRI)-resistant depression in adolescents, we conducted a randomized controlled trial evaluating alternative treatment strategies. In primary analyses, cognitive-behavioral therapy (CBT) combined with medication change was associated with higher rates of positive response to short-term (12-week) treatment than medication alone. This study examines predictors and moderators of treatment response, with the goal of informing efforts to match youths to optimal treatment strategies. Method: Youths who had not improved during an adequate SSRI trial (N= 334) were randomized to an alternative SSRI, an alternative SSRI plus CBT, venlafaxine, or venlafaxine plus CBT. Analyses examined predictors and moderators of treatment response. Results: Less severe depression, less family conflict, and absence of nonsuicidal self-injurious behavior predicted better treatment response status. Significant moderators of response to CBT + medication (combined) treatment were number of comorbid disorders and abuse history; hopelessness was marginally significant. The CBT/combined treatment superiority over medication alone was more evident among youths who had more cornorbid disorders (particularly attention-deficit/hyperactivity disorder and anxiety disorders), no abuse history, and lower hopelessness. Further analyses revealed a stronger effect of combined CBT + medication treatment among youths who were older and white and had no nonsuicidal self-injurious behavior and longer prestudy pharmacotherapy. Conclusions: Combined treatment with CBT and antidepressant medication may be more advantageous for adolescents whose depression is comorbid with other disorders. Given the additional costs of adding CBT to medication, consideration of moderators in clinical decision making can contribute to a more personalized and effective approach to treatment.

Original languageEnglish (US)
Pages (from-to)330-339
Number of pages10
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume48
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Serotonin Uptake Inhibitors
Cognitive Therapy
Depression
Therapeutics
Self-Injurious Behavior
Family Conflict
Attention Deficit Disorder with Hyperactivity
Anxiety Disorders
Antidepressive Agents
Randomized Controlled Trials
Costs and Cost Analysis
Drug Therapy

Keywords

  • Adolescents
  • Cognitive-behavioral therapy
  • Depression
  • Treatment-resistant

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Developmental and Educational Psychology

Cite this

Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents : Predictors and moderators of treatment response. / Asaknow, Joan Rosenbaum; Emslie, Graham; Clarke, Greg; Wagner, Karen; Spirito, Anthony; Vitiello, Benedetto; Iyengar, Satish; Shamseddeen, Wael; Ritz, Louise; Birmaher, Boris; Ryan, Neal; Kennard, Betsy; Mayes, Taryn; DeBar, Lynn; McCracken, James; Strober, Michael; Suddath, Robert; Leonard, Henrietta; Porta, Giovanna; Keller, Martin; Brent, David.

In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 48, No. 3, 03.2009, p. 330-339.

Research output: Contribution to journalArticle

Asaknow, JR, Emslie, G, Clarke, G, Wagner, K, Spirito, A, Vitiello, B, Iyengar, S, Shamseddeen, W, Ritz, L, Birmaher, B, Ryan, N, Kennard, B, Mayes, T, DeBar, L, McCracken, J, Strober, M, Suddath, R, Leonard, H, Porta, G, Keller, M & Brent, D 2009, 'Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: Predictors and moderators of treatment response', Journal of the American Academy of Child and Adolescent Psychiatry, vol. 48, no. 3, pp. 330-339. https://doi.org/10.1097/CHI.0b013e3181977476
Asaknow, Joan Rosenbaum ; Emslie, Graham ; Clarke, Greg ; Wagner, Karen ; Spirito, Anthony ; Vitiello, Benedetto ; Iyengar, Satish ; Shamseddeen, Wael ; Ritz, Louise ; Birmaher, Boris ; Ryan, Neal ; Kennard, Betsy ; Mayes, Taryn ; DeBar, Lynn ; McCracken, James ; Strober, Michael ; Suddath, Robert ; Leonard, Henrietta ; Porta, Giovanna ; Keller, Martin ; Brent, David. / Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents : Predictors and moderators of treatment response. In: Journal of the American Academy of Child and Adolescent Psychiatry. 2009 ; Vol. 48, No. 3. pp. 330-339.
@article{b9d83ac3e6124093ae9c0e667c853142,
title = "Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: Predictors and moderators of treatment response",
abstract = "Objective: To advance knowledge regarding strategies for treating selective serotonin reuptake inhibitor (SSRI)-resistant depression in adolescents, we conducted a randomized controlled trial evaluating alternative treatment strategies. In primary analyses, cognitive-behavioral therapy (CBT) combined with medication change was associated with higher rates of positive response to short-term (12-week) treatment than medication alone. This study examines predictors and moderators of treatment response, with the goal of informing efforts to match youths to optimal treatment strategies. Method: Youths who had not improved during an adequate SSRI trial (N= 334) were randomized to an alternative SSRI, an alternative SSRI plus CBT, venlafaxine, or venlafaxine plus CBT. Analyses examined predictors and moderators of treatment response. Results: Less severe depression, less family conflict, and absence of nonsuicidal self-injurious behavior predicted better treatment response status. Significant moderators of response to CBT + medication (combined) treatment were number of comorbid disorders and abuse history; hopelessness was marginally significant. The CBT/combined treatment superiority over medication alone was more evident among youths who had more cornorbid disorders (particularly attention-deficit/hyperactivity disorder and anxiety disorders), no abuse history, and lower hopelessness. Further analyses revealed a stronger effect of combined CBT + medication treatment among youths who were older and white and had no nonsuicidal self-injurious behavior and longer prestudy pharmacotherapy. Conclusions: Combined treatment with CBT and antidepressant medication may be more advantageous for adolescents whose depression is comorbid with other disorders. Given the additional costs of adding CBT to medication, consideration of moderators in clinical decision making can contribute to a more personalized and effective approach to treatment.",
keywords = "Adolescents, Cognitive-behavioral therapy, Depression, Treatment-resistant",
author = "Asaknow, {Joan Rosenbaum} and Graham Emslie and Greg Clarke and Karen Wagner and Anthony Spirito and Benedetto Vitiello and Satish Iyengar and Wael Shamseddeen and Louise Ritz and Boris Birmaher and Neal Ryan and Betsy Kennard and Taryn Mayes and Lynn DeBar and James McCracken and Michael Strober and Robert Suddath and Henrietta Leonard and Giovanna Porta and Martin Keller and David Brent",
year = "2009",
month = "3",
doi = "10.1097/CHI.0b013e3181977476",
language = "English (US)",
volume = "48",
pages = "330--339",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents

T2 - Predictors and moderators of treatment response

AU - Asaknow, Joan Rosenbaum

AU - Emslie, Graham

AU - Clarke, Greg

AU - Wagner, Karen

AU - Spirito, Anthony

AU - Vitiello, Benedetto

AU - Iyengar, Satish

AU - Shamseddeen, Wael

AU - Ritz, Louise

AU - Birmaher, Boris

AU - Ryan, Neal

AU - Kennard, Betsy

AU - Mayes, Taryn

AU - DeBar, Lynn

AU - McCracken, James

AU - Strober, Michael

AU - Suddath, Robert

AU - Leonard, Henrietta

AU - Porta, Giovanna

AU - Keller, Martin

AU - Brent, David

PY - 2009/3

Y1 - 2009/3

N2 - Objective: To advance knowledge regarding strategies for treating selective serotonin reuptake inhibitor (SSRI)-resistant depression in adolescents, we conducted a randomized controlled trial evaluating alternative treatment strategies. In primary analyses, cognitive-behavioral therapy (CBT) combined with medication change was associated with higher rates of positive response to short-term (12-week) treatment than medication alone. This study examines predictors and moderators of treatment response, with the goal of informing efforts to match youths to optimal treatment strategies. Method: Youths who had not improved during an adequate SSRI trial (N= 334) were randomized to an alternative SSRI, an alternative SSRI plus CBT, venlafaxine, or venlafaxine plus CBT. Analyses examined predictors and moderators of treatment response. Results: Less severe depression, less family conflict, and absence of nonsuicidal self-injurious behavior predicted better treatment response status. Significant moderators of response to CBT + medication (combined) treatment were number of comorbid disorders and abuse history; hopelessness was marginally significant. The CBT/combined treatment superiority over medication alone was more evident among youths who had more cornorbid disorders (particularly attention-deficit/hyperactivity disorder and anxiety disorders), no abuse history, and lower hopelessness. Further analyses revealed a stronger effect of combined CBT + medication treatment among youths who were older and white and had no nonsuicidal self-injurious behavior and longer prestudy pharmacotherapy. Conclusions: Combined treatment with CBT and antidepressant medication may be more advantageous for adolescents whose depression is comorbid with other disorders. Given the additional costs of adding CBT to medication, consideration of moderators in clinical decision making can contribute to a more personalized and effective approach to treatment.

AB - Objective: To advance knowledge regarding strategies for treating selective serotonin reuptake inhibitor (SSRI)-resistant depression in adolescents, we conducted a randomized controlled trial evaluating alternative treatment strategies. In primary analyses, cognitive-behavioral therapy (CBT) combined with medication change was associated with higher rates of positive response to short-term (12-week) treatment than medication alone. This study examines predictors and moderators of treatment response, with the goal of informing efforts to match youths to optimal treatment strategies. Method: Youths who had not improved during an adequate SSRI trial (N= 334) were randomized to an alternative SSRI, an alternative SSRI plus CBT, venlafaxine, or venlafaxine plus CBT. Analyses examined predictors and moderators of treatment response. Results: Less severe depression, less family conflict, and absence of nonsuicidal self-injurious behavior predicted better treatment response status. Significant moderators of response to CBT + medication (combined) treatment were number of comorbid disorders and abuse history; hopelessness was marginally significant. The CBT/combined treatment superiority over medication alone was more evident among youths who had more cornorbid disorders (particularly attention-deficit/hyperactivity disorder and anxiety disorders), no abuse history, and lower hopelessness. Further analyses revealed a stronger effect of combined CBT + medication treatment among youths who were older and white and had no nonsuicidal self-injurious behavior and longer prestudy pharmacotherapy. Conclusions: Combined treatment with CBT and antidepressant medication may be more advantageous for adolescents whose depression is comorbid with other disorders. Given the additional costs of adding CBT to medication, consideration of moderators in clinical decision making can contribute to a more personalized and effective approach to treatment.

KW - Adolescents

KW - Cognitive-behavioral therapy

KW - Depression

KW - Treatment-resistant

UR - http://www.scopus.com/inward/record.url?scp=62849116679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849116679&partnerID=8YFLogxK

U2 - 10.1097/CHI.0b013e3181977476

DO - 10.1097/CHI.0b013e3181977476

M3 - Article

C2 - 19182688

AN - SCOPUS:62849116679

VL - 48

SP - 330

EP - 339

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 3

ER -